Since the initial discovery of endothelial progenitor cells (EPC) applications, but much has to be learned about their nature, origin and properties.
INTRODUCTION
Once the vascular tree has grown to maturity, the endothelium remains in a rather quiescent state. However, during tissue repair after injury, in response to tissue growth or in pathological conditions neovascularization occurs, often as sprouting from the existing microvessels. In addition to this angiogenic process, it is generally believed that vasculogenesis can also contribute to neovascularization in the adult. and atherosclerosis 3, 4 . However, subsequent studies pointed to a limited participation of these circulating cells in the endothelial lining of newly grown vessels 5 and challenged the existence of EPC 67 .
At present, two different phenotypes of EPC have been recognized with predominant characteristics of either monocytic or endothelial cells. Here, we will briefly describe the characteristics of the different cell types that have been indicated as EPC. Subsequently, we will discuss current insights into the molecular mechanisms that are involved in mobilization and recruitment of progenitor cells to areas of neovascularization, with specific emphasis on the role of proteases and receptors.
IDENTITY OF ENDOTHELIAL PROGENITOR CELLS
On the basis of different cell culture protocols, immunohistochemical characterization, and flow cytometric analysis two different populations of EPC have been recognized. First, myeloid EPC are obtained when mononuclear cells from cord-or peripheral blood are cultured for 4 to 7 days in endothelial growth media. These cells that display both myeloid and endothelial cell markers most likely are derived from a subpopulation of monocytes and are also referred to as early-outgrowth cells.
A second EPC population is contained in the CD34 + /CD45 -cell fraction that circulates in low numbers. Upon culture in endothelial cell growth medium for about 14 days, a very minor number of these cells can develop into colonies of so-called late-outgrowth cells, also indicated as endothelial colony-forming cells (ECFC) 8 , or blood outgrowth endothelial cells (BOEC) 9 . These cells display the characteristics of mature endothelial cells, have a high proliferative capacity, and are able to form capillary-like structures. Both types of cells can contribute to neovascularization but the nature of their contribution is different. The myeloid EPC predominantly support angiogenesis and arteriogenesis in a paracrine fashion, whereas the late-outgrowth cells can physically incorporate into the endothelial lining of the new vascular structures (see also Hirschi et al 9 and Fadini et al 4 for review).
Cell culture and characterization of EPC
Ideally, EPC should be characterized by a combination of a specific set of surface antigens and functional properties that attribute specific endothelial functions to these cells. However, this goal has only partially been achieved, due to the limited number of cells initially available in the blood and the shift in (surface) protein expression during the maturation of these cells. 
Further characterization of different types of EPC
The antigen CD133+ has been suggested as a marker of stem/progenitor cells. 
MOBILIZATION OF ENDOTHELIAL PROGENITOR CELLS FROM THE BONE MARROW
The adult bone marrow is the principal reservoir of stem and progenitor cells, including hematopoietic and vascular precursors, such as endothelial progenitor cells.
Anatomically, two distinct zones can be recognized in the bone marrow, the osteo- Mice deficient of eNOS showed reduced VEGF-induced mobilization of EPC (CFU-EC) and increased mortality after myelosuppression. Mechanistically, MMP-9 activity was reduced in the bone marrow of eNOS -/-mice, because of reduced S-nitrosylation of MMP-9 55 . The importance of NO in progenitor cell function was further highlighted by the work from Sasaki et al 56 , who treated dysfunctional bone marrow cells from ischemic cardiomyopathy (ICMP) patients with the novel eNOS transcription enhancer AVE9488. AVE9488 increased eNOS mRNA levels and eNOS activity, which at least partially reversed the impaired functional activity of BMC, improving the neovascularization capacity of infused BMC in an ischemic hindlimb model in vivo.
Apart from VEGF and SDF-1, which are considered to be among the most effective mobilizers of EPC, a vast number of growth factors and cytokines have been described to modulate mobilization of EPC (CFU-EC) 57 . Granulocyte colony-stimulating factor (G-CSF), which has a strong stem/progenitor cell mobilizing potential, induces the release of elastase and cathepsin G from neutrophils, leading to the cleavage of adhesive bonds on bone marrow stromal cells 58, 59 . Moreover, these proteases can cleave and inactivate SDF-1, which is released by stromal cells and signals through its receptor CXCR4 on stem/progenitor cells 59, 60 . Similarly, G-CSF induced upregulation of the exopeptidase CD26 on CXCR4 + stem cells. CD26 is able to splice the N-terminal dipeptide from SDF-1, which causes inhibition of CXCR4 activation and reduced cell retention, resulting in an additional mechanism of mobilization 61, 62 .
A role for the plasminogen activator system in the recruitment and homing of CD34 
Mobilization of ECFC progenitors from the bone marrow.
Due to their low frequency and the incomplete characterization of the circulating precursors of ECFC, there is no information available at present on the origin and mobilization of cells that form the ECFC. It seems plausible these cells already develop into endothelial cell lineage in the bone marrow, in a process that requires VEGF and Notch signaling 66, 67 , and that their recruitment to the vascular niche of the bone marrow proceeds in a comparable way as that by other progenitor cells.
HOMING OF EPC TO AREAS OF NEOVASCULARIZATION
Recruitment of EPC to sites of neovascularization or endothelial injury strongly resembles that of an inflammatory response. Once in the vicinity of an injured vessel, EPC can interact with activated platelets, the damaged endothelial monolayer and components of the sub-endothelial matrix. This process has many similarities with the homing of leukocytes to the activated endothelium. This should not be surprising,
given that all studies on the homing of EPC have been done with cells that are CFU-EC and therefore largely, if not exclusively, myeloid in nature.
Homing and incorporation of EPC in the endothelial lining or sub-endothelial space is a multi-step process, which involves chemo-attraction, rolling and tethering of pro- and CXCL7 71, 72 , bradykinin 73 , macrophage migration inhibitory factor (MIF) 74 , and SDF-1/CXCL12 have been described to participate in EPC (CFU-EC) recruitment.
The latter one, SDF-1, and its specific receptor CXCR4 play a major role in stem cell recruitment and retention to ischemic areas [75] [76] [77] . In physiological conditions SDF-1 is constitutively expressed, but a range of stimuli such as inflammation 78 , tissue damage and hypoxia rapidly increase SDF-1 levels. SDF-1 is expressed or surface-bound at injured smooth muscle and endothelial cells, and is released by activated platelets [79] [80] [81] [82] . Activated platelets secrete high levels of SDF-1. Platelets are probably the first responders to vascular trauma and, after their adherence to subendothelial matrix structures and subsequent activation, release the necessary factors for progenitor cell mobilization and homing to the damaged area 
Retention of CD34 + progenitor cells by developing endothelial tubes in vitro
The interaction of EPC with capillary-like endothelial tubes can be mimicked in vitro in a three-dimensional fibrin-based tube formation assay 87 . We applied timelapse video microscopy to study the movement (chemokinesis) of peripheral and cord blood-derived CD34 + progenitor cells and the selective homing towards sites of tube formation (chemotaxis). The formation of tubes by human microvascular endothelial cells in a fibrin matrix was induced by addition of VEGF/TNF-a or bFGF/ TNF-a (see Figure 3) . Subsequently, the CD34 + progenitor cells were placed on top of the fibrin matrix covered with endothelial cells, which had started to form tubular structures. The CD34 + cells displayed a random movement over the stimulated endothelial monolayer during an 8-hour observation period. However, once the CD34 + cells reached a tubular structure they remained associated with that structure, either moving around in the tubule, or silently trapped. Quantification of these data (Table   1) showed that 80% of the cells that reached a tubular area were trapped, while in comparable control areas only 5% was present. Furthermore, the CD34 + cells entered as frequently a tube area as control areas of the same size and shape, suggesting chemokinesis rather than chemotaxis. However, one should note that the presence of serum, which contains large amounts of SDF-1, interfered likely with SDF-1-induced chemotaxis.
When the CD34 + cells were fixed with paraformaldehyde before adding them to the tube formation system, a complete arrest of the administered CD34 + cells on the stimulated endothelial monolayer was observed, indicating that the movement was 
Receptors involved in EPC (CFU-EC) homing to areas of angiogenesis in vivo
The initial adhesion of EPC (CFU-EC) seems to be mediated by injury/ischemiainduced upregulation of E-and P-selectin. A number of reports describe the expression analysis and in vivo blocking of P-and E-selectin, thereby attenuating the interaction with P-selectin glycoprotein ligand-1 (PSGL-1) on EPC (CFU-EC) B) . Again, the number of cells entering and being retained in these marked areas was counted. Further details and data of the quantification are given in Table 1 .
of EPC transplantation to induce neovascularization and salvage of the ischemic limb. Conversely, when E-selectin was knocked down by E-selectin small interfering RNA (siRNA), blood flow recovery after EPC transplantation was significantly impaired. The beneficial contribution of sE-selectin was further enhanced by stimulating ICAM-1 expression on endothelial cells 89 . In addition, Foubert et al 90 to E-selectin and P-selectin. In the case of more severe injury, when subendothelial matrix components are exposed, activated platelets and coagulation factors (fibrin) rapidly produce a microenvironment facilitating PSGL-1-mediated adhesion of CD34 + progenitor cells 82, 91, 92 .
Integrins expressed on the surface of EPC mediate the firm adhesion and transmigration of EPC to the damaged endothelium. Again, the murine model of hindlimb
ischemia was utilized to demonstrate that progenitor cells from β 2 -integrin-deficient mice are less capable of homing to sites of ischemia and of improving neovascula- by the fact that not only VLA-4 (α 4 β 1 integrin) and LFA-1 (α L β 2 integrin), but also their counterparts ICAM-1 and VCAM-1, were upregulated in ischemic tissue [94] [95] [96] .
Neutralization of one of these factors reduced adhesion and migration of EPC in vitro and reduced recovery of hindlimb blood flow, capillary density and incorporation of EPC into ischemic tissues in vivo [96] [97] [98] . Mechanistically, cell adhesion molecule (CAM)-integrin-mediated firm adhesion was reported being regulated by hypoxia as well as necrosis. High-mobility group box 1 (HMGB1) is a nuclear protein that is released extracellularly upon cell necrosis and tissue damage. Binding of HMGB1 to its receptor RAGE (receptor for advanced glycation end products) on EPC resulted in rapidly increased integrin affinity and induced integrin polarization, enhancing the in vitro adhesion and migration and in vivo homing and incorporation of EPC in the tumor vasculature 99 .
Exposure of endothelial cells to hypoxia increased the endogenous amount and kinase activity of the protein integrin-linked kinase (ILK-1) in a NFκB-and HIF-1α-dependent manner. Overexpression of ILK-1 resulted in ICAM-1 upregulation, whereas blocking ILK-1 abrogated the expression of ICAM-1 under hypoxia, with co-committed reduction in EPC homing and poor neovascularization in vivo 100, 101 .
In addition, the adipokine leptin, a published modulator of vascular remodeling and neointima formation, has recently been described to increase the expression of α V β 5 -and α 4 -integrins in EPC 102 .
Proteases involved in homing of EPC (CFU-EC)
Transmigration of EPC into the injured or hypoxic tissue is the last step of homing Finally, a role for the plasminogen system in EPC homing and recruitment was anticipated. Xiang et al 114 investigated the potential of the plasminogen system in vivo.
Blocking the protease inhibitor plasminogen-activator inhibitor-1 (PAI-1) with a sequence-specific DNA enzyme at the time of myocardial infarction resulted in increased engraftment of exogenously delivered CD34 + progenitors in the infarct zone.
Abrogation of the natural inhibition of PAI-1 on u-PA was most likely responsible for the observed effect 114 .
Homing of ECFC progenitors
The circulating progenitors of ECFC are likely cells that can be recruited to areas of neovascularisation and tissue repair. Their endothelial nature makes a direct interaction and incorporation in the endothelial lining possible. However, one would expect that the circulating counterpart of ECFC must be able to recognize an area in need of (neo)vascularisation support, and to home to and migrate into it. Recent studies suggested that the combination of CFU-EC and ECFC was more effective in stimulating neovascularisation and tissue repair, also pointed to a directed influx and action of the ECFC 36115 , albeit that this issue remains controversial.
While no information is presently available on homing receptors, it is likely that these cells use similar proteases as other endothelial cells, such as MT1-MMP, MMP-2, MMP-9 and the urokinase/plasmin system 116 . These proteases are indeed expressed in ECFC. Cultured ECFC displayed relatively high u-PA and MMP-2 levels compared to normal endothelial cells 105117 . Inhibition of ECFC-associated u-PA by monoclonal antibodies that block u-PA activity or binding to its receptor significantly reduced proliferation, migration and capillary-like tube formation in vitro
PARTICPATION OF EPC IN THE NEWLY FORMED VESSELS
A number of studies using various animal models have suggested that bone marrowderived and circulating progenitor cells are capable of repopulating within damaged organs, possibly contributing to angiogenesis (see Tanaka et al  118 , and Zampetaki et   al  103 for review) . However, the contribution of bone marrow-derived EPC to neovascularization has been seriously challenged by other groups, who found no evidence for such a process in tumor vascularization in mice 67 . Differences in the evaluation at early and late time points, reflecting a contribution in the initial phase only, and the fact that the ECFC are so few that they are not easily encountered in mice may in part explain these differences 119 . If EPC and ECFC may contribute to angiogenesis and/or vasculogenesis, they can do so at three levels. First, they can provide growth factors or other signals that stimulate and orchestrate the angiogenesis process. Second, ECFC can enforce the endothelial lining of preexisting and newly formed vessels by being incorporated in the endothelial lining (intussuseption). Finally, ECFC can organize themselves into new vascular structures that connect to the resident circulation.
Intussuseption of circulating EPC in healing human blood vessels
The extent to which endothelial progenitors contribute to human angiogenesis and vascular maintenance is still a matter of controversy 120, 121 . The identification of gen- tochemical analysis revealed that these cells were in fact macrophages 122 . Indeed, after damage of the vasculature, monocytes can spread over the exposed vessel matrix, an initial coverage that later can be replaced by endothelial cells. More decisive was a small but significant amount of reports based on sex-mismatched bone marrow transplantations, which suggested that human bone marrow-derived EPC incorporate into tumor vessels 5, 123 , skin 124 , endometrium 125 and transplanted hearts and livers [126] [127] [128] [129] [130] . In all these studies only very low numbers of cells (usually less than 1-5%) were encountered in the endothelial lining of healthy, small blood vessels.
Vascular injury, as occurs at sites of atherosclerotic plaque development, or after myocardial infarction, increased the number of incorporated bone marrow-derived cells to a various degree 127, 130 . A time course of endocardial biopsies demonstrated that their was neither an increase nor a decrease in the number of incorporated cells over a 10-year period 129 . 
Contribution of late-outgrowth ECFC

